The Price of a Forged Prescription: Ruti Aga Banned for Six Years, and the Substance the Media Misnamed

Addis Ababa. The Athletics Integrity Unit (AIU) has banned Ethiopian marathon runner Ruti Aga for six years. According to the statement issued on Thursday, the sanction is the sum of two separate violations: two years for the presence of a prohibited substance in her sample, and four years for tampering — providing misleading information to investigators and submitting a forged medical prescription. The ban is dated from 10 September, the same date on which she was provisionally suspended.

On the surface this looks like a straightforward doping case. Look closer and it is a knot of three different stories. First, a case involving one of the most common sports-medicine treatments in existence, one that has been consistently misdescribed in technical terms. Second, a deep failure of medical governance inside the entourages that surround East African road runners. Third, a penalty that is legally coherent but whose severity deserves scrutiny.

What the case actually is

According to the AIU, Aga's sample was collected after a half marathon in China in March, which she won. The sample contained methylprednisolone. During the investigation she cited a knee injury and produced a medical prescription as evidence of treatment. The investigation found the prescription to be forged. Per the AIU, it was issued under the name of a clinic that did not exist, by a 'doctor' who was a family member with no medical registration. Questioned, that person claimed to have used an 'old prescription pad from a former workplace' — and the clinic named on the pad explicitly disowns the claim.

So three independent verification failures occurred in a single case: the existence of the clinic, the registration of the practitioner, and the authenticity of the document. The AIU proceeded on two grounds: presence of a prohibited substance, and tampering — attempting to mislead the investigative process with false material. The second charge proved far heavier than the first.

The arithmetic: two plus four

The architecture of the sanction matters, because it reveals how the panel reasoned. The two years cover the presence violation. For substances classified as 'Specified Substances' on the World Anti-Doping Agency (WADA) list — which includes methylprednisolone — the standard sanction is two years where intent is not proven. The four years cover tampering, the standard penalty under the World Anti-Doping Code. The sum is plain: 2 + 4 = 6.

But there is something concealed inside that arithmetic. Had the athlete been able to show no significant fault — that she was genuinely injured, the treatment genuine, and only the timing rules misunderstood — the presence sanction could have been reduced, potentially to a reprimand. The panel granted no such mitigation. The reason is simple: the moment she produced a forged document, she destroyed her own strongest legal defence.

It is also worth noting that counting from 10 September is not a discount. Time served under provisional suspension is credited against the ban, so the athlete gains nothing in real terms. It is a procedural adjustment, not a reduction.

The substance that was misnamed

A technical correction is necessary here, because it has been widely repeated across coverage of this case. Methylprednisolone has been described as a 'prohibited steroid' and it has been claimed that WADA classifies it as performance enhancing. That is imprecise and misleading. Methylprednisolone is a glucocorticoid — class S9 on the WADA list — not an anabolic steroid, which sits in class S1. The two are chemically distinct, act differently, and are governed by different rules.

Most importantly, under the current list S9 glucocorticoids are prohibited in-competition only, and only when administered by injection, orally, or rectally. A therapeutic knee injection given out of competition is entirely legal. It becomes a violation only if residues are present in a sample taken in competition.

Which means the entire case rested not on 'steroid use' but on two very ordinary questions: by what route was the drug administered, and how long before the competition. In road racing the testing window opens at 23:59 the day before the race, so an injection given days earlier can still be caught. Any analysis of this case that skips that technical detail will run in the wrong direction. And that is the central irony: Aga had a legitimate defence available — an explanation of timing, route and medical necessity. She closed that route herself with forged paperwork.

The knee injury: the real root, and a systemic gap

The least discussed aspect of this case is where it began. Knee inflammation and its treatment by injection are routine among distance runners. The heavy volume of marathon training places relentless load on the joint, and a glucocorticoid injection is the cheapest, most available and fastest form of relief. The athlete's medical explanation was, technically, credible.

And precisely because it was credible, the forgery becomes decisive. If the treatment genuinely happened, it could have been documented with real records. The absence of real records is itself the signal that medical support was informal rather than formal. The 'doctor' who wrote the prescription was a relative, not a registered physician. That is not a clerical slip; it is a direct indicator of an athlete competing internationally with no credentialed team physician and no medical infrastructure.

The related question is the Therapeutic Use Exemption (TUE). An athlete whose knee is a persistent problem requiring regular injections has two paths: obtain or apply for a TUE, or strictly observe WADA's route-specific washout period. Had either been followed, there would be no case at all. The decision to forge a prescription implies that neither path was available or known.

One further point must be added: the four-year tampering charge rests not on a document alone but on statements made during investigation. It is an interview-based charge. Language and interpretation conditions in AIU interviews with Ethiopian athletes have repeatedly been a point of contention. How much that factor mattered here is not clear from the public statement, but it cannot be dismissed entirely.

Career accounting: Tokyo 2026 survives, the 2028 cycle does not

Aga is 32. With the ban dated from 10 September, she would be eligible to return at roughly 38. Given the depth of Ethiopian women's marathoning, a 38-year-old returning athlete with a doping record should be regarded as effectively unselectable for the national team. At elite level the ban is technically six years but functionally a lifetime one.

Her record? She won the 2026 Tokyo Marathon, her biggest title. She also has three second-place finishes at World Marathon Majors. Public records place her best performance in the region of 2:18 to 2:20, though the AIU statement gives no mark, and that figure should not be treated as confirmed in this report. What is confirmed is that she was a genuinely elite marathoner of her era, and that is the bitterness of this case.

There is an important legal point most reports have skipped. The violation is anchored to the March race, which came after 2026. Absent evidence of earlier use, results before that date — including the 2026 Tokyo win — are not automatically annulled. The AIU statement does not set out the disqualification scope. It would therefore be wrong to assume her entire career has been erased. Commercially, however, the distinction may not matter much: in a sport where distance-running sponsorship is already thin, a banned athlete's name becomes a liability.

Results and prize money: what the statement does not say

The AIU statement does not explicitly state whether her result and prize money from the March half marathon have been annulled. Standard practice, however, is clear: the competition at which the sample was collected is automatically disqualified, and ranking points accrued thereafter are forfeited. That is the reasonable expectation in practice, even if the statement's language does not spell it out.

A similar technical caution applies to dates. The statement does not explicitly record the year of the March race or the precise expiry date of the ban. References such as 'provisionally suspended since 10 September' and 'statement on Thursday' strongly imply the current year, but this is not stated directly in the text. That care matters in reporting, because dates are the basis of the entire calculation in this case.

Ethiopia's depth and China's label circuit

Competitively, the ban has no effect on the picture in women's marathoning. Ethiopia has an entire generation at world-record level; Kenya has a deep pool capable of converting at championships. The removal of a 32-year-old with no global championship medal changes nothing in Ethiopian selection calculus.

The shift is elsewhere — in enforcement. Her positive sample came at a half marathon in China, which she won. That is not coincidental. Asia's label-race circuit has long been an attractive, comparatively low-risk income tier for East African marathoners between major races — a direct route to a good appearance fee. But that same tier is now the AIU's highest-yield testing ground. The appearance-fee economy and the testing economy are colliding in the same races.

And a pattern emerges here that deserves serious attention. A two-year sanction for presence is routine. But whenever a case reaches documents, sanctions suddenly jump. That suggests the enforcement frontier has shifted from detection to verification. It is likely that more such cases will surface, because the same informal medical network serving one training cluster serves many athletes.

One thing absent from the statement is worth noting: no response from the Ethiopian federation is quoted. No action is mentioned against any person or agent who advised on or accepted the forged document. The AIU named only the family member. Whether the entourage's role was investigated remains an open question. It is possible for an athlete to construct such a case alone; but in a system that includes managers, agents and local support staff, placing responsibility on the athlete alone is an incomplete picture.

The appeal route: open, but of limited value

Legally, Aga has an appeal route. Typically, an appeal can be filed with the Court of Arbitration for Sport (CAS) within about three weeks of the reasoned decision. But the prospects here look weak, because the tampering finding rests on documentary evidence, and documentary evidence is very hard to overturn. Challenging the presence finding is harder still — the sample was positive, and that fact will not change. What can be argued is the quantum of the sanction, and even there the defence would need to show that a legitimate medical necessity lay behind the forgery — which she made impossible.

There is a separate risk outside the AIU's jurisdiction: document forgery can also be a criminal matter, and could be referred to national authorities. No such referral is mentioned in the statement, but the possibility exists.

The larger question: proportionality and perspective

Here is an uncomfortable fact. Methylprednisolone is a substance with no proven benefit to endurance performance. It reduces inflammation and reduces pain — it is treatment, not enhancement. And it is in a case involving this substance that a six-year ban, driven by the forgery, has been imposed. That outcome will be read two ways.

On one hand, it is evidence of AIU rigour: tampering with documents will not be tolerated under any circumstances, however minor the underlying substance. That message is necessary, because the credibility of the entire anti-doping system rests on athletes not resorting to lies to escape testing.

On the other hand, it will be read as evidence of disproportionality: a question will be raised about how strictly enforcement falls on African road runners, and how few resources they have to defend themselves. An athlete with a credentialed team physician, legal advisers and media management reaches a different outcome from the same position. One with nothing reaches for an old prescription pad.

The right conclusion is therefore not that a dishonest athlete was caught. It is that an injured athlete, whose knee was a long-standing problem, was caught inside a medical system that did not know the rules and that solved the problem by inventing paperwork. The original fault was not the knee, and not the drug — the original fault was that no professional around her existed to tell her what the correct path was. The six-year ban is the price of that absence.